
    
      This study is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled,
      dose-ranging, efficacy and safety study, designed to document the clinical benefit of
      ataluren when administered as therapy of patients with DMD/BMD due to a nonsense mutation
      (premature stop codon) in the dystrophin gene.
    
  